Videos

Here are the top 5 biosimilars articles for the week of April 27, 2020.

Christine Simmon talks about whether or not biosimilar uptake will happen as rapidly as it did for generics at the recent FDA/Federal Trade Commission workshop on anticompetitive practices.

Two IPD Analytics pharmacy experts discuss the ever-growing number of Humira (adalimumab) biosimilars, how developers are trying to stand out from the crowd, and the potential for the first-ever interchangeable biosimilar.

Two IPD Analytics pharmacy experts give us their take on the overall biosimilar pipeline, but also on how incoming insulin products are positioned for success.

Here are the top 5 biosimilars articles for the week of April 20, 2020.

Molly Burich, MS, head of public policy at Boehringer Ingelheim (BI), discusses how the FDA's new guidance on interchangeability designation will improve confidence and acceptance for biosimilars during the World Biosimilar Congress USA 2020 at the Festival of Biologics USA in San Diego, California.

Molly Burich, MS, head of public policy at Boehringer Ingelheim, discusses the why there currently are no biosimilars with an interchangeability designation during the World Biosimilar Congress USA 2020 at the Festival of Biologics USA in San Diego, California..

Will Gatziolis, MBA, an associate principal at ZS, talks how the coronavirus (COVID-19) pandemic will help biosimilar uptake and what manufacturers can do to take advantage of this opportunity.

Ruby Singh, vice president for Education and Training, Academy of Managed Care Pharmacy (AMCP), speaks with Mary Caffrey about the upcoming AMCP eLearning Days, a virtual meeting that will take place April 20 to 24. AMCP's annual meeting was canceled due to coronavirus disease 2019 (COVID-19). This transcript is edited slightly for clarity.

Here are the top 5 biosimilars articles for the week of April 13, 2020.

Surya Singh, MD discusses how education efforts have reduced providers’ doubts surrounding the similarity between biosimilars and their reference products at the March 2020 FDA/Federal Trade Commission workshop on anticompetitive practices.

Sarfaraz Niazi, PhD, an adjunct professor of biopharmaceutical Sciences at the College of Pharmacy at the University of Illinois at Chicago, discusses how the COVID-19 (coronavirus) pandemic is affecting drug shortages, challenging the FDA, and creating an greater opportunity for biosimilars down the road.

The Center for Biosimilars® recaps the top stories for the week of April 6, 2020.

Surya Singh, MD, discussed dynamics that affect biosimilar uptake on the medical benefits side and how that differs from the pharmacy benefits side at the recent FDA/Federal Trade Commission workshop on anticompetitive practices.

Soumi Saha, PharmD, JD, senior director of advocacy at Premier, Inc, discusses drug shortages caused by coronavirus disease (COVID-19) and policy recommendations that could fix the problem.

The Center for Biosimilars® recaps the top stories for the week of March 30, 2020.

Christine Simmon discussed the Purple Book and how it will affect biosimilar makers and illuminate patent hurdles at the recent FDA/Federal Trade Commission workshop on anticompetitive practices.

Matt Harman talks about what employers can do to help promote biosimilar adoption in the United States, during the World Biosimilar Congress USA 2020 at the Festival of Biologics USA in San Diego, California.

The Center for Biosimilars® recaps the top stories for the week of March 23, 2020.

Matt Harman talks about employer interest in biosimilar promotion and how the FDA's new biologics pathway change will affect interest levels, during the World Biosimilar Congress USA 2020 at the Festival of Biologics USA in San Diego, California.

Wayne Winegarden, PhD, talked about the issues and benefits of the FDA's switch to a biologics regulatory pathway for certain products, especially insulin, during the World Biosimilar Congress USA 2020 at the Festival of Biologics USA in San Diego, California.

Sheila Frame, the vice president of marketing, market access, and patient services at Sandoz, discusses US biosimilar policies in development and the impact they will have on the market at the World Biosimilar Congress 2020 at the Festival of Biologics USA in San Diego, California.

Wayne Winegarden, PhD discusses the potential savings inherent in biosimilars at the World Biosimilar Congress 2020 at the Festival of Biologics USA in San Diego, California.

The Center for Biosimilars® recaps the top stories for the week of March 2, 2020.

Gillian Woollett, MA, DPhil, senior vice president, Avalere Health, explains the importance of consistency in applying critical product quality attributes.

Using biosimilars to reduce costs of cancer care is necessary, says Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at MD Anderson Cancer Center.

Gillian Woollett, MA, DPhil, senior vice president, Avalere Health, explains potential consequences if the United States were to do away with biosimilars.

Lindsey Roeker, MD, clinical fellow at Memorial Sloan Kettering Cancer Center, discusses adding rituximab to venetoclax to allow for a 2-year fixed-duration treatment schedule for patients with chronic lymphocytic leukemia (CLL).

Brian Lehman, MBA, MHA, RPh, director, Medical Account Management and Strategic Alliances, Sandoz, discusses the March 2020 transition of insulin to the biologics pathway.

Cate Lockhart, PharmD, PhD, discusses the research reports the Biologics and Biosimilars Collective Intelligence Consortium (BBCIC) plans on releasing in 2020.